Integrating TYK2 Inhibitors into the Psoriasis Treatment Algorithm

In ‘Integrating TYK2 Inhibitors into the Psoriasis Treatment Algorithm,’ our panel explores how the emergence of TYK2 inhibitors has reshaped the traditional hierarchy of psoriasis care. Dr. Mark Lebwohl explains that while he rarely utilizes older TNF blockers due to their boxed warnings for cancer and infection, he views newer IL-17 and IL-23 blockers as highly effective standards of care. He notes that the choice between a TYK2 inhibitor and a biologic often centers on patient preference for a daily oral pill versus an injection every few months. Dr. Lebwohl acknowledges that while some biologics may peak faster than oral agents, TYK2 inhibitors offer a remarkably safe profile that avoids the yeast infection risks associated with IL-17 inhibitors.

The experts also delve into advanced management strategies, including the off-label use of deucravacitinib in combination with biologics. Dr. Lebwohl references published data showing that patients who failed to reach "treat to target" goals on a single agent experienced significant improvement when a TYK2 inhibitor was added. Dr. Tina Bhutani-Jacques agrees, noting that she often employs combination therapy for complex cases involving both skin and psoriatic arthritis where monotherapy proves insufficient. Furthermore, the discussion touches on the expanding pipeline of oral therapies, including envudeucitinib, which recently reported phase 3 results. The panelists emphasize that having a variety of available TYK2 inhibitors is essential for clinical practice, likening the need for multiple options to having a diverse range of antibiotics to ensure every patient can find a successful long-term treatment.

Our next episode, ‘Potential Therapeutic Opportunities of TYK2 Therapy Beyond Psoriasis and Identifying the Ideal Patient,’ features the panelists discussing the long-term systemic benefits of reducing inflammation and the promising future of TYK2 inhibitors for comorbidities. Dr. Bhutani-Jacques and Dr. Lebwohl also identify key patient profiles, such as those with needle phobia or active lifestyles, who benefit most from oral treatment options.